Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery

Medtronic Cardiovascular91 enrolled

Overview

This clinical study has been developed to evaluate the clinical outcomes in patients undergoing coronary artery bypass grafting via Minimally Invasive Coronary Surgery (MICS); a minimally invasive coronary bypass procedure that is done on a beating heart via a smaller chest incision, thus avoiding the invasiveness of the standard procedure.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Arteriosclerosis of Coronary Artery Bypass Graft

Interventions

Minimally invasive coronary artery bypass graft surgeryPROCEDURE

The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \> or equal to 18 and \< or equal to 80 years of age * Suitable minimally invasive coronary surgery (MICS) candidate for non-emergent first time, single or multivessel coronary artery bypass grafting (on pump or off pump) * Left ventricle ejection fraction \>30% * Willing and able to provide written informed consent and comply with study requirements Exclusion Criteria: * Severe cerebrovascular disease within 90 days of surgery including history of prior stroke. * Previous cardiac surgery procedures such as CABG revisions, surgical ablations or valve replacements * Congestive heart failure with a New York Heart Association (NYHA) Class IV * History of renal insufficiency (i.e. prior serum creatinine of \>2mg/dl) and/or requiring dialysis * Uncontrolled diabetes (i.e. \>2 serum glucose concentrations of \>350 mg/dl) * Severe uncontrolled systemic hypertension (i.e. systolic pressure \>160 mmHg) * Peripheral/systemic active infection excluding the patient from cardiac surgery * Life expectancy of less than 1 year due to other illness such as cancer or pulmonary, hepatic or renal disease * Participation in another investigational protocol that may confound the results of this study * Female of child bearing potential and lactating or intends to become pregnant during the study * Severe distal disease and small posterior lateral targets

Locations (2)

Staten Island University Hospital

Staten Island, New York, United States

University of Ottawa Heart Institute

Ottawa, Ontario, Canada

Outcomes

Primary Outcomes

Technical Success (Graft Patency) in a MICS Approach

For each subject, the endpoint for technical success (graft patency) in a MICS approach is defined as acceptable flow for graft size for an anastamosis. This will be characterized by the surgeon's assessment/angiography after the graft is complete.

Time frame: At time of procedure (day 1)

Procedural Success in a MICS Approach

A successful procedure can be defined as a procedures not requiring conversion (sternotomy). This will be characterized by whether the graft procedure can be completed through the minimally invasive thoracotomy without having to convert to a sternotomy in order to complete the grafting.

Time frame: At time of procedure (day 1)

Patency of the Index Graft at 6 Months

For each subject, the endpoint is the percent of stenosis collected on the subject's 6 month angiography form. This will be characterized for each graft using the FitzGibbon scoring system based on the 64-Slice CT Angiography results. The FitzGibbon Scoring system is as follows: A:Excellent graft with unimpaired runoff (\< 50% stenosis) B:Stenosis reducing caliber of proximal or distal anastomoses or trunk to \<50% of the grafted coronary artery. O:Occluded (100% stenosed)

Time frame: 6 months post-procedure

Composite Major Adverse Event Rate (Early)

During procedure and within 30 days post-procedure or hospital discharge, whichever is longer. The adverse events will include: * Major hemorrhage/bleeding requiring surgical intervention * Aortic complications * Graft vessel revision (GVR) * Transient ischemic attacks (TIA) * Cerebrovascular accidents (CVA)/stroke * Myocardial infarction (MI) * Death

Time frame: During procedure (day 1) and within 30 days post-procedure or hospital discharge, whichever is longer (throughout 6 month evaluation)

Secondary Outcomes

Composite Major Adverse Event Rate (Late)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.